Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Why did Nvidia reach $4 trillion market cap? How will Trump's copper tariffs impact US economy? What caused recent recall of Ritz cracker sandwiches? Why is Apple COO Jeff Williams stepping down? How are Trump’s tariffs affecting global trade deals? What led to Merck’s $10 billion Verona Pharma acquisition? Why was FTC ‘click-to-cancel’ rule blocked by court?

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
July 9, 2025 6:30 am ET
Acquisition aligns with Merck’s science-led business development…

This story appeared on merck.com, 2025-07-09 12:31:51.480000.